恒瑞瑞普泊肽III期成功
2026-07-21 04:23:02
据界面新闻报道，7月20日，恒瑞医药宣布，GLP-1/GIP双重受体激动剂瑞普泊肽注射液治疗中国2型糖尿病初治人群的III期临床试验取得积极顶线结果，主要终点及所有关键次要终点均达到优效。公司计划近期在中国提交该药用于成人2型糖尿病患者血糖控制的新药上市申请。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Next article：
SEMI上调半导体设备销售预测
